Humira Savings on the Horizon? by Robert Kordella, RPh, MBA, Chief Clinical Officer In 2021, Humira (adalimumab) amassed $21 billion in sales in the U.S.

Some Good News Due to Upcoming Generics by Robert Kordella, RPh, MBA, Chief Clinical Officer Not all of the news is bad in the world

Medication Adherence: Is it a Waste of Money? by Shavsha Davis, Assistant Vice President There is an old proverb that says, “An apple a day

Diabetes: What’s driving non-specialty trend? by Matt Jarvis, PharmD, Vice President, Pharmacy Practice Leader As specialty pharmacy continues to outpace other healthcare benefits spend, the

Dispense As Written Prescription Instructions and Their Impact on Plan Sponsors and Participants by Joe Schmidt, MBA, Vice President | Team Lead   Before the

Common Sense Management of Narcolepsy and Cataplexy by Bob Kordella, R.Ph., MBA, Chief Clinical Officer  The Mayo Clinic provides a simple definition of narcolepsy and

November 30, 2020:Where We Are Today And When Will New Vaccines Be Approved? by Bob Kordella, R.Ph., MBA, Chief Clinical Officer Worldwide there were 48